Tema Etfs LLC Acquires New Position in Stryker Co. (NYSE:SYK)

Tema Etfs LLC acquired a new stake in shares of Stryker Co. (NYSE:SYK - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 798 shares of the medical technology company's stock, valued at approximately $287,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. J. W. Coons Advisors LLC increased its stake in Stryker by 0.7% in the 4th quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company's stock valued at $1,315,000 after purchasing an additional 26 shares in the last quarter. Mascoma Wealth Management LLC increased its stake in Stryker by 22.7% in the 4th quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company's stock valued at $53,000 after purchasing an additional 27 shares in the last quarter. Opal Wealth Advisors LLC increased its stake in Stryker by 1.6% in the 4th quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company's stock valued at $654,000 after purchasing an additional 28 shares in the last quarter. Lindbrook Capital LLC increased its stake in Stryker by 2.0% in the 4th quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company's stock valued at $507,000 after purchasing an additional 28 shares in the last quarter. Finally, JFS Wealth Advisors LLC increased its stake in Stryker by 4.4% in the 4th quarter. JFS Wealth Advisors LLC now owns 687 shares of the medical technology company's stock valued at $247,000 after purchasing an additional 29 shares in the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the sale, the director now directly owns 3,417,326 shares of the company's stock, valued at approximately $1,288,195,208.96. The trade was a 5.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.90% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Wells Fargo & Company raised their price objective on Stryker from $427.00 to $435.00 and gave the company an "overweight" rating in a research note on Wednesday, January 29th. Needham & Company LLC reiterated a "buy" rating and set a $442.00 target price on shares of Stryker in a research report on Friday, March 21st. Stifel Nicolaus lifted their price target on Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a report on Wednesday, January 29th. The Goldman Sachs Group set a $422.00 price objective on shares of Stryker in a report on Tuesday, March 4th. Finally, Roth Mkm increased their price objective on shares of Stryker from $405.00 to $456.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Five investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $427.05.

Stryker Stock Down 2.4%

Shares of SYK traded down $9.53 during midday trading on Wednesday, reaching $380.02. 1,459,714 shares of the company were exchanged, compared to its average volume of 1,347,642. The stock has a 50-day moving average price of $367.95 and a 200-day moving average price of $375.92. The company has a market cap of $145.05 billion, a price-to-earnings ratio of 48.97, a P/E/G ratio of 2.93 and a beta of 0.93. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. The company had revenue of $5.87 billion for the quarter, compared to analysts' expectations of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The firm's quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.50 earnings per share. Research analysts expect that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.88%. The ex-dividend date is Monday, June 30th. Stryker's dividend payout ratio is presently 45.41%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.